Pharming Group NV (PHAR)

Currency in USD
17.80
+0.12(+0.68%)
Closed·
17.800.00(0.00%)
·
PHAR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.5618.41
52 wk Range
8.0321.34
Key Statistics
Prev. Close
17.68
Open
18.36
Day's Range
17.56-18.41
52 wk Range
8.03-21.34
Volume
4.13K
Average Vol. (3m)
27.16K
1-Year Change
120.0247%
Book Value / Share
0.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHAR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
34.60
Upside
+94.38%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins

Pharming Group NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Employees
407

Compare PHAR to Peers and Sector

Metrics to compare
PHAR
Peers
Sector
Relationship
P/E Ratio
446.4x−4.2x−0.5x
PEG Ratio
3.630.000.00
Price / Book
4.6x3.7x2.6x
Price / LTM Sales
3.4x4.3x3.2x
Upside (Analyst Target)
109.3%69.2%45.7%
Fair Value Upside
Unlock7.6%4.8%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 34.60
(+94.38% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
0.07 / 0.05
Revenue / Forecast
106.5M / 101.76M
EPS Revisions
Last 90 days

PHAR Income Statement

People Also Watch

40.120
LQDA
+3.64%
87.45
HEIJ
-1.02%
92.78
IMCD
+1.75%
63.86
DSFIR
+1.24%
6.24
FFARM
-1.27%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.